0001181431-11-036129.txt : 20110610 0001181431-11-036129.hdr.sgml : 20110610 20110610170613 ACCESSION NUMBER: 0001181431-11-036129 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110609 FILED AS OF DATE: 20110610 DATE AS OF CHANGE: 20110610 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HASTINGS DAVID C CENTRAL INDEX KEY: 0001237401 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12400 FILM NUMBER: 11906358 MAIL ADDRESS: STREET 1: 50 AVENUE GENERAL DE GAULLE CITY: BRUXELLES STATE: C9 ZIP: 9999999999 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INCYTE CORP CENTRAL INDEX KEY: 0000879169 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 943136539 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ROUTE 141 & HENRY CLAY ROAD STREET 2: BUILDING E336 CITY: WILMINGTON STATE: DE ZIP: 19880 BUSINESS PHONE: 3024986700 MAIL ADDRESS: STREET 1: ROUTE 141 & HENRY CLAY ROAD STREET 2: BUILDING E336 CITY: WILMINGTON STATE: DE ZIP: 19880 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE CORP DATE OF NAME CHANGE: 20030318 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE GENOMICS INC DATE OF NAME CHANGE: 20000710 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930902 4 1 rrd314930.xml X0303 4 2011-06-09 0 0000879169 INCYTE CORP INCY 0001237401 HASTINGS DAVID C EXPERIMENTAL STATION ROUTE 141 & HENRY CLAY ROAD WILMINGTON DE 19880 0 1 0 0 Chief Financial Officer Common Stock 2011-06-09 4 M 0 100000 5.12 A 108500 D Common Stock 2011-06-09 4 S 0 25000 17.70 D 83500 D Common Stock 2011-06-09 4 S 0 25000 17.73 D 58500 D Common Stock 2011-06-09 4 S 0 25000 17.75 D 33500 D Common Stock 2011-06-09 4 S 0 25000 17.76 D 8500 D Non Qualified Stock Option (right to buy) 5.12 2011-06-09 4 M 0 81876 0 D 2013-10-13 Common Stock 81876 0 D Incentive Stock Option (right to buy) 5.12 2011-06-09 4 M 0 18124 0 D 2013-10-13 Common Stock 18124 60000 D Beginning October 14, 2003, options became exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. /s/ David C. Hastings 2011-06-10